Form 4: Royalty Pharma Executive Acquires Shares via Equity Award
Insider Transaction Report
Royalty Pharma's EVP of Investments & CLO, George W. Lloyd, acquired 6,168 Class A Ordinary Shares through an equity award settlement.
Summary
- George W. Lloyd, Executive Vice President, Investments & Chief Legal Officer of Royalty Pharma plc, acquired 6,168 Class A Ordinary Shares.
- The transaction occurred on November 5, 2025, and was an exempt acquisition pursuant to Rule 16b-3.
- The shares were acquired in connection with the settlement of Equity Performance Awards at a price of $0 per share.
- The transaction was made pursuant to a Rule 10b5-1(c) plan, indicating a pre-arranged purchase or sale plan.
- Following this transaction, George W. Lloyd beneficially owns a total of 1,135,341.19 Class A Ordinary Shares, held directly and indirectly through various entities and a spouse.
Sentiment
Score: 7
Explanation: The acquisition of shares by a key executive, even through equity awards, generally signals confidence in the company's future and aligns management's interests with those of shareholders.
Positives
- The acquisition of shares by a key executive, even through equity awards, generally signals confidence in the company's future.
- Increased insider ownership aligns management's interests with those of shareholders.
Future Outlook
The filing does not provide any forward-looking statements or guidance beyond the scheduled transaction date.
Industry Context
This filing reflects a routine executive compensation event, where equity performance awards are settled into company shares, a common practice across various industries to incentivize and retain key management personnel.
Related Party Transactions
- Acquisition of 6,168 Class A Ordinary Shares by EVP, Investments & CLO George W. Lloyd as settlement of Equity Performance Awards.
Stakeholder Impact
- Shareholders: Increased insider ownership may enhance alignment of interests between management and shareholders.
Key Dates
| Date | Description |
|---|---|
| 11/05/2025 | Date of earliest transaction (acquisition of 6,168 Class A Ordinary Shares) |
| 11/07/2025 | Signature date of the reporting person |
Keywords
Royalty Pharma, RPRX, Insider Transaction, Form 4, Equity Award, Executive Compensation, Rule 10b5-1
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.